Application of PD-1 Blockade in Cancer Immunotherapy

The programmed cell death protein 1 (PD-1) pathway has received considerable attention due to its role in eliciting the immune checkpoint response of T cells, resulting in tumor cells capable of evading immune surveillance and being highly refractory to conventional chemotherapy. Application of anti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Computational and structural biotechnology journal Jg. 17; S. 661 - 674
Hauptverfasser:	Wu, Xiaomo, Gu, Zhongkai, Chen, Yang, Chen, Borui, Chen, Wei, Weng, Liqiang, Liu, Xiaolong
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Netherlands Elsevier B.V 01.01.2019 Research Network of Computational and Structural Biotechnology Elsevier
Schlagworte:	antibodies biotechnology Checkpoint blockade clinical trials commercialization drug therapy immune evasion Immune surveillance immunosuppression Immunotherapy monitoring neoplasm cells neoplasms patients PD-1 PD-L1 programmed cell death Review T-lymphocytes cTnI PTPs CXCL9 PMBCL IHC ITT PTEN MHC HR UC NF-κB DNMT PI3K Immunotherapy PFS TIM3 B2M JMJD3 LAG3 cHL DOR 5-AZA-dC HCC PKC SIRPα ITIM GEJ DCM ZAP70 TGF RCC CRC LCK HNSCC PD-1 MSI-H ASCT MAP ERK TCR TIICs DZNep ORR AEs NFAT IFN SHP2 BV DCs PD-L1 CTLA-4 GC ICOS Checkpoint blockade ADCC IrAEs dMMR CC SCLC APCs AP1 NSCLC OS VEGF ITSM ICC TMB BICR Immune surveillance MCC TME BATF PRC2 TILs EZH2 TGF, Transforming growth factor PKC, Protein kinase C AP1, Activator protein 1 MAP, Mitogen-activated protein LAG3, Lymphocyte-activation gene 3 HR, Hazard ratio BV, Brentuximab vedotin DOR, Duration overall response SIRPα, Signal-regulatory protein alpha DCs, Dendritic cells HCC, Hepatocellular carcinoma JMJD3, Jumonji Domain-Containing Protein 3 PMBCL, Primary mediastinal large B-cell lymphoma NFAT, Nuclear factor of activated T cells DZNep, 3-Deazaneplanocin A ICC, Investigator-choice chemotherapy ITSM, Immune-receptortyrosine-based switch motif NF-κB, Nuclear factor-κB dMMR, DNA mismatch repair deficiency SCLC, Small cell lung cancer PFS, Progression-free survival cTnI, Cardiac troponin I TMB, Tumor mutation burden ICOS, Inducible T-cell co-stimulator TIM3, T-cell immunoglobulin and mucin-domain containing-3 BATF, Basic leucine zipper transcriptional factor ATF-like ITIM, Immune-receptortyrosine-based inhibitory motif PD-L1, Programmed death-ligand 1 PTPs, Protein tyrosine phosphatases MSI-H, Microsatellite instability-high TME, Tumor microenvironment ERK, Extracellular signal–regulated kinase ITT, Intention-to-treat ZAP70, Zeta-chain-associated protein kinase 70 TCR, T-cell receptor B2M, β2 microglobulin OS, Overall survival ADCC, Antibody-dependent cellular cytotoxicity BICR, Blinded Independent Central Review CTLA-4, Cytotoxic T-lymphocyte–associated antigen 4 PD-1, Programmed cell death 1 cHL, Classical Hodgkin lymphoma DCM, Dilated cardiomyopathy NSCLC, Non-small cell lung cancer 5-AZA-dC, 5-aza-2′-deoxycytidine EZH2, Enhancer of zeste homolog 2 HNSCC, Head and neck squamous cell carcinoma CC, Cervical cancer ORR, Overall response rate GC, Gastric cancer PRC2, Polycomb repressive complex 2 RCC, Renal cell carcinoma TIICs, Tumor infiltrating immune cells PTEN, Phosphatase and tensin homolog ASCT, Autologous stem cell transplantation APCs, Antigen presenting cells IHC, Immunohistochemistry LCK, Tyrosine-protein kinase Lck VEGF, Vascular endothelial growth factor GEJ, GASTRIC or gastroesophageal junction PI3K, Phosphoinositide 3-kinase SHP2, Src homology 2 domain-containing phosphatase 2 CXCL9, C-X-C motif chemokine ligand 9 IFN, Interferon IrAEs, Immune related adverse events DNMT, DNA methyltransferase AEs, Adverse events MCC, Merkel cell carcinoma MHC, Major histocompatibility TILs, Tumor-infiltrating lymphocytes UC, Urothelial carcinoma CRC, Colorectal cancer
ISSN:	2001-0370, 2001-0370
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!